Aspectos das Leveduras de Candida Vinculadas as ... - NewsLab
Aspectos das Leveduras de Candida Vinculadas as ... - NewsLab
Aspectos das Leveduras de Candida Vinculadas as ... - NewsLab
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
49. Pow<strong>de</strong>rly WG et al. Amphotericin B-resistant ye<strong>as</strong>ts infection in severely immunocompromised patients. Am. J. Med.<br />
84: 826-832, 1988.<br />
50. Prince MF et al. Plate Methods for <strong>de</strong>tection of phospholip<strong>as</strong>e activity in C. albicans. Sabouraudia 20: 15-20, 1982.<br />
51. Pugh D, Cawson RA. The cytochemical localization of phospholip<strong>as</strong>e A and lysophospholip<strong>as</strong>e in C. albicans. Sabouraudia,<br />
13: 110-115, 1975.<br />
52. Quirino MRS. Estudo clínico e microbiota fúngica da cavida<strong>de</strong> bucal <strong>de</strong> diabéticos controlados e não controlados.<br />
54f. Mest. Fac. <strong>de</strong> Odontologia, Univ. <strong>de</strong> Taubaté-SP,1990.<br />
53. Ray RL, Payne CD. Characterization of an acid prote<strong>as</strong>e produced by C. albicans and related species. Clin. Res. 30:<br />
801-A, 1982.<br />
54. Remold H et al. Purification and characterization of a proteolytic enzyme from C. albicans. Biochim. Biophys. Acta,<br />
167: 399-408, 1968.<br />
55. Ribeiro EL et al. Detecção <strong>de</strong> C. albicans fosfolipidolític<strong>as</strong> isola<strong>d<strong>as</strong></strong> da saliva <strong>de</strong> crianç<strong>as</strong> com síndrome <strong>de</strong> Down. Acta<br />
Méd. Portuguesa 15(3): 171-174, 2002.<br />
56. Ribeiro MA. Exoenzim<strong>as</strong> e mecanismos moleculares <strong>de</strong> resistência fluconazol <strong>de</strong> C. albicans isola<strong>d<strong>as</strong></strong> <strong>de</strong> mulheres<br />
HIV positiv<strong>as</strong>. 156f. Mest. ICB-USP. S. Paulo, 2002.<br />
57. Ruchel R et al. A comparison of secretory protein<strong>as</strong>es from different strains of C. albicans. Sabouraudia, 20: 233-<br />
244, 1982.<br />
58. Saballs P et al. La candi<strong>de</strong>mia en el síndrome <strong>de</strong> inmuno<strong>de</strong>ficiencia adquirida. Estudio retrospectivo <strong>de</strong> nueve c<strong>as</strong>os.<br />
Rev. Iberoameric. <strong>de</strong> Micologia, 17(1): 2-5, 2000.<br />
59. Samaranayake LP et al. Factors affecing the phospholip<strong>as</strong>e activity of <strong>Candida</strong> species in vitro. Sabouraudia, 22:<br />
201-207, 1984.<br />
60. Sanchez ML, Jones RN. Etest na antimicrobial susceptibity testing method with broad clinical and epi<strong>de</strong>miologic<br />
aplication. Antimicrobic. Newsletter 8: 1-7, 1993.<br />
61. Sandven P, Bjorneklett A. Susceptibilities of norwegian C. albicans strains to fluconazole: emergence of resistence.<br />
Antimicrob. Agents Chemother.; 37: 2443-2448; 1993.<br />
62. Sheehan DJ et al. Current and emerging azole antifungal agents. Clinical Microbiolog. Research. 12(1): 40-79, 1999.<br />
63. Silva P. Farmacologia. 6ª ed. Ed. Guanabara Koogan. Rio <strong>de</strong> Janeiro, RJ, 1997. p. 1120.<br />
64. Silveira FRX et al. Protein<strong>as</strong>e and phospholip<strong>as</strong>e activity of C. albicans isolated form oral mucosa of healthy carriers<br />
(smokers and non smokers). Rev. Iber. Micol., 10: 105-108, 1993.<br />
65. Souza EMB et al. <strong>Aspectos</strong> morfo-fisiológicos, fatores <strong>de</strong> virulência e sensibilida<strong>de</strong> a antifúngicos <strong>de</strong> amostr<strong>as</strong> <strong>de</strong> C.<br />
albicans, sorotipos A e B, isola<strong>d<strong>as</strong></strong> em S. Paulo, Br<strong>as</strong>il. Rev. Microbiol.: 21:247-253, 1990.<br />
66. Staib F. Serum proteins <strong>as</strong> nitrogen source for yest-like fungi. Sabouraudia, 4: 187-193,1965.<br />
67. Tavares W. Manual <strong>de</strong> antibióticos e quimioterápicos antiinfecciosos. S. Paulo, Ed. Ateneu, 1 o ed. 1993. 478p.<br />
68. Van<strong>de</strong>r Bossche H et al. Mechanisms and clinical impact of antifungal drug resistance. J. Med. Veter. Mycol. 32 (supl.<br />
1): 189-202, 1994.<br />
69. V Fend. Bula do Produto. New York, NY. Pfizer Inc. March. 2002.<br />
70. Warnock DW. Azole drug resistance in <strong>Candida</strong> species. J. Med. Microbiol. 37: 225-226, 1992.<br />
71. Werner H. Untersuchunger uber die lip<strong>as</strong>e-aktivitat bei hefen und hefeahnliehen pilzen. Zbl. Bakt. Hyg. I. Abt. A. 200:<br />
113-24, 1966.<br />
72. White TC et al. Clinical cellular and molecuar factos that contribute to antifungal drug resistence. Clin. Microbiol. Rev.:<br />
11: 382-402, 1998.<br />
73. Zaitz C et al. Compêndio <strong>de</strong> micologia médica. Médica e Científica Ltda, 1998. 434p.<br />
128<br />
<strong>NewsLab</strong> - edição 64 - 2004
Change language